TRANSLATIONAL SCIENCES INC.
Paradise Valley, AZ · Biotech · Private
Ultra-specific monoclonal antibody inhibitor of matrix metalloproteinase-9 (MMP-9) for ischemic stroke treatment
- Grants
- $19M
- 17 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 12
- 4 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20142016201820202022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Novel Methods for Dissolving Blood Clots | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Methods for Dissolving Blood Clots | $5,000 | |
| Federal grant | Department of Health and Human Services · Phase I · HLS Potent, novel inhibitor of fibrinolytic hemorrhage | $351,119 | |
| Federal grant | Department of Health and Human Services · Phase I · HLS Potent novel inhibitor of fibrinolytic hemorrhage | $351,119 | |
| Federal grant | Department of Health and Human Services · Phase II · HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II | $2,812,000 | |
| Federal grant | Department of Health and Human Services · Phase II · HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II | $423,216 | |
| Federal grant | Department of Health and Human Services · Phase II · HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II | $1,321,017 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke | $336,200 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke | $336,200 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercialization Readiness Pilot for Amplifying Fibrinolysis in Ischemic Stroke | $1,646,140 | |
| Federal grant | Department of Health and Human Services · Phase II · HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II | $1,067,767 | |
| Federal grant | Department of Health and Human Services · Phase II · Commercialization Readiness Pilot for Amplifying Fibrinolysis in Ischemic Stroke | $1,713,006 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial | $1,408,991 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial | $1,408,690 | |
| Federal grant | Department of Health and Human Services · Phase II · Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke | $1,161,162 | |
| Federal grant | Department of Health and Human Services · Phase II · Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke | $2,444,197 | |
| Federal grant | Department of Health and Human Services · Phase II · Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke | $1,283,035 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1836 | Alzamend Neuro, Inc. | — | $232K |
| 1837 | Superior Genomics, Inc. | — | $508K |
| 1838 | CONCEPTION HOLDINGS, INC. | — | $50K |
| 1839 | TRANSLATIONAL SCIENCES INC. | — | — |
| 1840 | Entelo, Inc. | — | $4.9M |
| 1841 | KDAc Therapeutics, Inc. | — | — |
| 1842 | SCRIPT BIOSCIENCES INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Serpinf2-Binding Molecules and Method of Use Thereofapplication
- Inhibition of Vascular Matrix Metalloproteinase-9 to Treat Ischemic Injuryapplication
- Inhibition of Vascular Matrix Metalloproteinase-9 to Treat Ischemic Injurygranted
- Serpinf2-Binding Molecules and Method of Use Thereofgranted
- Prophylaxis of Thrombosisgranted
- Method Of Increasing Plasmin Activity Through Antiplasmin Conversiongranted
- Selective Inhibition of Vascular Matrix Metalloproteinase-9 to Reduce Ischemic Injuryapplication
- Matrix METALLOPROTEINASE-9 Inhibitor And Treatment Of Strokeapplication
- Inhibition Of Vascular Matrix METALLOPROTEINASE-9 To Treat Ischemic Injuryapplication
- Matrix METALLOPROTEINASE-9 Inhibitor And Treatment Of Strokeapplication
- Prophylaxis Of Thrombosisapplication
- Prophylaxis Of Thrombosisapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.